/PRAX
PRAX Stock - Praxis Precision Medicines, Inc.
Healthcare|BiotechnologyNASDAQ
$272.92+1.36%
+$3.66 (+1.36%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.1
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+56.6%upside
Target: $427.39
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PRAX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$270.19 – $275.65
TARGET (TP)$427.40
STOP LOSS$251.09
RISK/REWARD1:7.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.98
52W High$282.99
52W Low$26.70
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $8.55M | $2.45M | N/A | N/A | N/A |
| Gross Profit | $-143,860,000 | $-84,319,000 | $-154,440,000 | N/A | N/A |
| Gross Margin | -1682.0% | -3445.8% | N/A | N/A | N/A |
| Operating Income | $-200,165,000 | $-126,373,000 | $-214,986,000 | $-167,332,000 | $-61,968,000 |
| Net Income | $-182,819,000 | $-123,277,000 | $-214,029,000 | $-167,061,000 | $-61,820,000 |
| Net Margin | -2137.5% | -5037.9% | N/A | N/A | N/A |
| EPS | $-10.21 | $-18.69 | $-69.33 | $-58.96 | $-103.61 |
Company Overview
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
11
92%
Hold / Neutral
1
8%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
11 Bullish1 Neutral/Bearish
Price Targets
$178
Average Target
↓ 34.9% Downside
Now
$4
Low
$178
Average
$750
High
Based on 12 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 15th 2025 | Oppenheimer | Reiterated | Outperform | $750← $250 |
| November 19th 2025 | BTIG Research | Initiation | Buy | $424 |
| June 2nd 2025 | Oppenheimer | Resumed | Outperform | $97 |
| May 7th 2025 | Chardan Capital Markets | Initiation | Buy | $80 |
| March 3rd 2025 | H.C. Wainwright | Reiterated | Buy | $105← $120 |
| February 11th 2025 | Deutsche Bank | Initiation | Buy | $111 |
| August 5th 2024 | Oppenheimer | Initiation | Outperform | $134 |
| June 24th 2024 | Needham | Initiation | Buy | $145 |
| June 18th 2024 | Guggenheim | Initiation | Buy | $155 |
| May 1st 2024 | Robert W. Baird | Initiation | Outperform | $117 |
| September 19th 2023 | Truist | Initiation | Buy | $10 |
| June 6th 2022 | Wedbush | Downgrade | Neutral | $4 |
Earnings History & Surprises
PRAXBeat Rate
39%
Last 18 quarters
Avg Surprise
-3.9%
EPS vs Estimate
Beats / Misses
7/11
Last 12 quarters
Latest EPS
$-3.36
Q4 2025
EPS Surprise History
Q1 24
+5.7%
$-2.97vs$-3.15
Q2 24
-41.3%
$-2.84vs$-2.01
Q3 24
+26.9%
$-1.74vs$-2.38
Q4 24
-36.8%
$-2.75vs$-2.01
Q1 25
-6.5%
$-2.94vs$-2.76
Q2 25
-2.8%
$-3.29vs$-3.20
Q3 25
+2.6%
$-3.31vs$-3.40
Q4 25
+2.6%
$-3.36vs$-3.45
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 30, 2026 | — | — | — | — |
Q1 2026 | Feb 27, 2026 | $-3.00 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-3.45 | $-3.36 | +2.6% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | $-3.40 | $-3.31 | +2.6% | ✓ BEAT |
Q2 2025 | May 2, 2025 | $-3.20 | $-3.29 | -2.8% | ✗ MISS |
Q1 2025 | Feb 28, 2025 | $-2.76 | $-2.94 | -6.5% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-2.01 | $-2.75 | -36.8% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-2.38 | $-1.74 | +26.9% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-2.01 | $-2.84 | -41.3% | ✗ MISS |
Q1 2024 | Mar 5, 2024 | $-3.15 | $-2.97 | +5.7% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-5.25 | $-2.70 | +48.6% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-9.90 | $-7.35 | +25.8% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-11.24 | $-10.64 | +5.3% | ✓ BEAT |
Q1 2023 | Feb 7, 2023 | $-10.94 | $-13.04 | -19.2% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-13.79 | $-14.39 | -4.4% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-19.49 | $-19.79 | -1.5% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-19.34 | $-22.64 | -17.1% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-16.19 | $-19.49 | -20.4% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $-13.94 | $-14.99 | -7.5% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-10.19 | $-13.19 | -29.4% | ✗ MISS |
Latest News
Oppenheimer Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $750
📈 PositiveBenzinga•Dec 15, 2025, 05:24 PM
Praxis Precision Medicines Completes Planned Discussion With FDA Leading To Confirmation To File NDA For Relutrigine In Early 2026
📈 PositiveBenzinga•Dec 11, 2025, 01:06 PM
Praxis Precision Medicines Announces Alignment With FDA On Simplified And Accelerated Registrational Pathway For Elsunersen
📈 PositiveBenzinga•Dec 9, 2025, 09:03 PM
Guggenheim Maintains Buy on Praxis Precision Medicine, Raises Price Target to $760
📈 PositiveBenzinga•Dec 9, 2025, 12:41 PM
Praxis Precision Medicines Reports FDA Alignment On Ulixacaltamide NDA; Reports EMBOLD Results For Relutrigine With 53% Seizure Reduction, And Vormatrigine RADIANT Study Shows Up To 100% Weekly Seizure Reduction In Focal Onset Seizures; Monotherapy Study, POWER3, Is On Track To Begin In First Half Of 2026
📈 PositiveBenzinga•Dec 8, 2025, 09:51 PM
Praxis Precision Medicine shares are trading higher after multiple analyst firms raised their respective price targets on the stock.
📈 PositiveBenzinga•Dec 8, 2025, 04:53 PM
TD Cowen Maintains Buy on Praxis Precision Medicine, Raises Price Target to $353
📈 PositiveBenzinga•Dec 8, 2025, 04:35 PM
Truist Securities Maintains Buy on Praxis Precision Medicine, Raises Price Target to $500
📈 PositiveBenzinga•Dec 8, 2025, 03:37 PM
Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $315
📈 PositiveBenzinga•Dec 8, 2025, 12:51 PM
HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $340 Price Target
📈 PositiveBenzinga•Dec 8, 2025, 12:21 PM
BTIG Maintains Buy on Praxis Precision Medicine, Raises Price Target to $507
📈 PositiveBenzinga•Dec 8, 2025, 10:41 AM
Praxis Precision Medicines shares are trading higher after the company announced the completion of its pre-NDA meeting with the FDA and it gained alignment from the agency. The company announced results from the registrational cohort of the EMBOLD study evaluating relutrigine for the treatment of patients with SCN2A and SCN8A developmental and epileptic encephalopathies.
📈 PositiveBenzinga•Dec 5, 2025, 01:53 PM
Wedbush Maintains Underperform on Praxis Precision Medicine, Raises Price Target to $83
➖ NeutralBenzinga•Dec 5, 2025, 01:41 PM
HC Wainwright & Co. Maintains Buy on Praxis Precision Medicine, Raises Price Target to $340
📈 PositiveBenzinga•Dec 5, 2025, 12:41 PM
Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $304
📈 PositiveBenzinga•Dec 5, 2025, 12:36 PM
Market-Moving News for December 5th
➖ NeutralBenzinga•Dec 5, 2025, 12:24 PM•Also: ,
Praxis Precision Medicines shares are trading higher after the company announced the completion of its pre-NDA meeting with the FDA and it gained alignment from the agency. The company announced results from the registrational cohort of the EMBOLD study evaluating relutrigine for the treatment of patients with SCN2A and SCN8A developmental and epileptic encephalopathies.
📈 PositiveBenzinga•Dec 4, 2025, 09:27 PM
Praxis Precision Medicines Reports EMBOLD Trial Stopped Early For Efficacy In SCN2A/SCN8A Developmental And Epileptic Encephalopathies, Plans FDA Meeting And Dec. 6 Topline Data Presentation
📈 PositiveBenzinga•Dec 4, 2025, 09:13 PM
Praxis Precision Medicines Secures FDA Alignment In Pre-NDA Meeting, Plans NDA Submission In Early 2026
📈 PositiveBenzinga•Dec 4, 2025, 09:04 PM
Needham Reiterates Buy on Praxis Precision Medicine, Maintains $250 Price Target
📈 PositiveBenzinga•Dec 1, 2025, 10:37 AM
Frequently Asked Questions about PRAX
What is PRAX's current stock price?
Praxis Precision Medicines, Inc. (PRAX) is currently trading at $272.92 per share. The stock has moved +1.36% today.
What is the analyst price target for PRAX?
The average analyst price target for PRAX is $427.40, based on 1 analyst.
What sector is Praxis Precision Medicines, Inc. in?
Praxis Precision Medicines, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PRAX's market cap?
Praxis Precision Medicines, Inc. has a market capitalization of $5.77 billion, making it a mid-cap company.
Does PRAX pay dividends?
No, Praxis Precision Medicines, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACAD
ACADIA Pharmaceuticals Inc.
$27.16
Mkt Cap: $4.6B
AKRO
Akero Therapeutics, Inc.
$54.65
Mkt Cap: $4.5B
CNTA
Centessa Pharmaceuticals plc
$24.85
Mkt Cap: $3.3B
CRNX
Crinetics Pharmaceuticals, Inc.
$48.01
Mkt Cap: $4.6B
IMVT
Immunovant, Inc.
$26.68
Mkt Cap: $4.7B
KYMR
Kymera Therapeutics, Inc.
$83.99
Mkt Cap: $6.0B
LGND
Ligand Pharmaceuticals Incorporated
$200.33
Mkt Cap: $3.9B
SLNO
Soleno Therapeutics, Inc.
$47.85
Mkt Cap: $2.6B
VKTX
Viking Therapeutics, Inc.
$35.19
Mkt Cap: $4.0B
XENE
Xenon Pharmaceuticals Inc.
$44.10
Mkt Cap: $3.4B
Explore stocks similar to PRAX for comparison